Today's Date: June 3, 2023
INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of DZS Inc. (DZSI) on Behalf of Investors   •   SENTINELONE ALERT: Bragar Eagel & Squire, P.C. is Investigating SentinelOne, Inc. on Behalf of SentinelOne Stockholders and   •   The Assembly of First Nations and the Government of Canada announce updates to school design standards for schools on-reserve   •   Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y   •   ETHNIC CONFLICTS IN NIGERIA: UNMASKING THE PUPPET MASTERS   •   San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat   •   Rapid Dose Announces Proposed Private Placement Financing   •   FNKO INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Funko, Inc. Investors with Substantial Losses Have Opp   •   Statement from Minister Hutchings on progress in support of rural Canadians   •   INVESTOR ALERT: Law Offices of Howard G. Smith Continues Investigation of SentinelOne, Inc. (S) on Behalf of Investors   •   HESAI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Hesai   •   Bijou Ikli named new CEO by Florida Assisted Living Association   •   BURGERFI DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Bu   •   Kirby McInerney LLP Reminds Investors That a Class Action Lawsuit Has Been Filed on Behalf of LivePerson, Inc. (LPSN) Investors   •   SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Funko, Inc. with Losses of $100,000 to Contact the Firm   •   CURE HOSTS "AI FOR GOOD" SUPER SESSION TO MAKE SENSE OF BIG DATA AND HIGH TECH AT 2023 BIO INTERNATIONAL CONVENTION ON JUNE 5   •   56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award   •   Navidea Biopharmaceuticals, Inc. Receives NYSE American Notice   •   Hilton brings back exclusive pop-up hotel experience 'Hilton on the Green' to the 2023 RBC Canadian Open   •   UNice Celebrates LGBTQ Pride Month
Bookmark and Share

New Data show NEUROMARK® Chronic Rhinitis Treatment Offers Significant Symptom Improvements

GALWAY, Ireland , March 21 /Businesswire/ - Neurent Medical, a company pioneering innovative non-surgical interventions to treat chronic inflammatory sinonasal diseases, today announced three-month data from the CLARITY study, a prospective, single-arm, multicenter safety and efficacy study of its NEUROMARK® System for patients with chronic rhinitis. These data, published in Laryngoscope Investigative Otolaryngology, show that patients receiving the NEUROMARK therapy demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months.

Approximately one in four Americans have chronic rhinitis1, a condition that results in persistent congestion, rhinorrhea (runny nose), sneezing, and nasal itching caused by inflammation and swelling of the mucosal membrane in the nose. NEUROMARK’s unique device and intelligent technology platform enable otolaryngologists to treat chronic rhinitis with precision and control, which in turn allows for an enhanced patient experience from treatment through recovery.

The CLARITY Study enrolled thirty-six participants and all completed follow-ups at one and three months. Primary endpoints were device-related serious adverse events (SAEs) at 1 month and change from baseline in visual analog scale nasal symptom scale (VAS NSS) for rhinorrhea and nasal congestion at 3 months. Total Nasal Symptom Score (rTNSS) and mini Rhinoconjunctivitis Quality of Life Questionnaire (mini RQLQ) score were also evaluated.

The data demonstrated the following benefits of NEUROMARK’s posterior nasal nerve (PNN) ablation procedure at 3 months post procedure:

  • The mean VAS NSS scores for rhinorrhea and nasal congestion significantly improved from baseline (both p<0.0001), achieving a mean percent change of 53% and 55%, respectively.
  • Total rTNSS scores and all individual items demonstrated significant improvement (all p<0.001).
  • Percent responder rate (≥30% reduction from baseline in total rTNSS) was 78%.
  • Total mean mini RQLQ scores and all subdomains improved significantly (p<0.0001).
  • 89% of participants reported a minimal clinically important difference (MCID) of ≥0.4 point improvement in the mini RQLQ score.
  • No serious adverse events occurred during the study, and there were no reports of epistaxis or headaches.

“People living with chronic rhinitis have had limited options when traditional therapies fail. Other therapies on the market don’t always adequately address symptoms for every patient,” said Douglas D. Reh, MD, FARS, Otolaryngology Specialist at ENT Associates and the study’s principal investigator. “The data showed statistically significant and clinically meaningful improvement in symptoms and quality of life assessments at 3 months post NEUROMARK procedure.”

NEUROMARK is designed to gently apply controlled low-power radio frequency (RF) energy to target regions of the nasal cavity, disrupting the parasympathetic nerve signals that can trigger an inflammatory response. This unique system offers ENTs a novel and unique leaflet design to help deliver precision neurolysis of posterior nasal nerves, with the intelligence and flexibility to comfortably accommodate a range of anatomies.

“We’re encouraged by the three-month CLARITY data demonstrating the safety, efficacy and relief from chronic rhinitis symptoms that can be achieved with NEUROMARK,” said Neurent Medical CEO Brian Shields. “I’m grateful to Dr. Reh and each of the study’s investigators for adding to the growing body of clinical evidence supporting PNN for these patients.”

The NEUROMARK System has received U.S. Food and Drug Administration (FDA) clearance and Neurent Medical announced the limited market release of the system in February 2023.

About Neurent Medical

Neurent Medical is pioneering innovative treatments for chronic inflammatory sinonasal diseases by targeting and safely disrupting hyperactive autonomic nerves that drive underlying inflammation. Its proprietary NEUROMARK® technology with a unique design and advanced algorithmic control, physicians can precisely target and safely disrupt multiple underlying nerve branches in a single procedure to alleviate Chronic Rhinitis symptoms and improve patient quality of life. The venture capital-backed company is headquartered in Galway, Ireland. For more information visit

1 Settipane RA, Charnock DR. Epidemiology of rhinitis: allergic and nonallergic. Clin Allergy Immunol. 2007;19:23-34. PMID: 17153005.

STORY TAGS: Biotechnology, General Health, Health, Medical Devices, Business Update, Product/Service, Europe, Ireland, United States, North America,


White House Live Stream
Breaking News
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Sounds Make the News ®
Atlanta - WAOK-Urban
Berkley / San Francisco - KPFA-Progressive
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
Washington - WOL-Urban

Listen to United Natiosns News